About Sight Sciences Inc
Ticker
info
SGHT
Trading on
info
NASDAQ
ISIN
info
US82657M1053
Industry
info
Medical Devices
Sector
info
Healthcare
CEO
info
Paul Badawi
Headquarters
info
4040 Campbell Avenue, Menlo Park, CA, United States, 94025
Employees
info
216
Website
info
sightsciences.com
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform a comprehensive procedure indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, as well as for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and SION surgical instrument, a bladeless manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The company also provides TearCare system, a dry eye device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Metrics
BasicAdvanced
Market cap
info
$345M
P/E ratio
info
-
EPS
info
-$0.90
Dividend Yield
info
0.00%
Beta
info
2.46
Forward P/E ratio
info
0
EBIDTA
info
$-44.8M
Ex dividend date
info
-
Price & volume
Market cap
info
$345M
Average daily volume
info
0.3M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
4.53
Price to book
info
4.35
Earnings
EPS
info
-$0.90
EPS estimate (current quarter)
info
-$0.26
EPS estimate (next quarter)
info
-$0.25
EBITDA
info
$-44.8M
Revenues (TTM)
info
$76.1M
Revenues per share (TTM)
info
$1.48
Technicals
Beta
info
2.46
52-week High
info
$7.12
52-week Low
info
$2.03
50-day moving average
info
$4.02
200-day moving average
info
$3.46
Short ratio
info
10.16
Short %
info
2.63%
Management effectiveness
ROE (TTM)
info
-57.91%
ROA (TTM)
info
-21.82%
Profit margin
info
-60.63%
Gross profit margin
info
$65.4M
Operating margin
info
-39.71%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
-1.20%
Share stats
Outstanding Shares
info
52.9M
Float
info
29.4M
Insiders %
info
20.34%
Institutions %
info
50.67%
Analyst Insights & forecasts
info

25% Buy

75% Hold

0% Sell

Based on information from 8 analysts.

Average price target

info
$5.75
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.23
-$0.18
-30.68%
Q4 • 24Missed
-$0.28
-$0.28
-
Q1 • 25Beat
-$0.23
-$0.26
11.54%
Q2 • 25Beat
-$0.16
-$0.26
38.46%
Q3 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$19.6M
$-11.9M
-61.04%
Q2 • 25
$19.9M
$-8.2M
-41.04%
Q3 • 25
1.75%
-31.59%
-32.76%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$122M
$52M
42.60%
Q2 • 25
$116M
$52M
44.70%
Q3 • 25
-4.69%
0.01%
4.93%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-7.5M
$-0.2M
$0.5M
$-7.8M
Q2 • 25
$-8.7M
-
$0M
$-8.9M
Q3 • 25
15.59%
-
-94.85%
14.65%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Sight Sciences Inc share?
Collapse

Sight Sciences Inc shares are currently traded for undefined per share.

How many shares does Sight Sciences Inc have?
Collapse

Sight Sciences Inc currently has 52.9M shares.

Does Sight Sciences Inc pay dividends?
Collapse

No, Sight Sciences Inc doesn't pay dividends.

What is Sight Sciences Inc 52 week high?
Collapse

Sight Sciences Inc 52 week high is $7.12.

What is Sight Sciences Inc 52 week low?
Collapse

Sight Sciences Inc 52 week low is $2.03.

What is the 200-day moving average of Sight Sciences Inc?
Collapse

Sight Sciences Inc 200-day moving average is $3.46.

Who is Sight Sciences Inc CEO?
Collapse

The CEO of Sight Sciences Inc is Paul Badawi.

How many employees Sight Sciences Inc has?
Collapse

Sight Sciences Inc has 216 employees.

What is the market cap of Sight Sciences Inc?
Collapse

The market cap of Sight Sciences Inc is $345M.

What is the P/E of Sight Sciences Inc?
Collapse

The current P/E of Sight Sciences Inc is null.

What is the EPS of Sight Sciences Inc?
Collapse

The EPS of Sight Sciences Inc is -$0.90.

What is the PEG Ratio of Sight Sciences Inc?
Collapse

The PEG Ratio of Sight Sciences Inc is null.

What do analysts say about Sight Sciences Inc?
Collapse

According to the analysts Sight Sciences Inc is considered a hold.